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Abstract
The expression of telomerase activity and the in situ
localization of the human telomerase RNA component
( )hTR in melanocytic skin lesions was evaluated in
specimens from sixty-three patients. Specimens of
melanocytic nevi, primary melanomas and subcuta-
neous metastases of melanoma were obtained from
fifty-eight patients, whereas metastasized lymph nodes
were obtained from five patients. Telomerase activity
was determined in these specimens by using a Poly-
( )merase Chain Reaction–based assay TRAP . High rela-
tive mean telomerase activity levels were detected in
(metastatic melanoma subcutaneous metastasess54.5,
)lymph node metastasess56.5 . Much lower levels were
detected in primary melanomas, which increased with
(advancing levels of tumor cell penetration Clark IIs
)0.02, Clark IIIs1.1, and Clark IVs1.9 . Twenty-six for-
malin-fixed, paraffin-embedded melanocytic lesions
were sectioned and analyzed for telomerase RNA with a
radioactive in situ hybridization assay. In situ hy-
bridization studies with a probe to the template RNA
component of telomerase confirmed that expression
was almost exclusively confined to tumor cells and not
infiltrating lymphocytes. These results indicate that lev-
els of telomerase activity and telomerase RNA in
melanocytic lesions correlate well with clinical stage
and could potentially assist in the diagnosis of border-
line lesions.
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Introduction
Telomeres, the chromosomal end regions composed of
[ ]tandem repeats of the sequence TTAGGG in vertebrates 1
are believed to be important in stabilizing the chromosomes
[ ]during replication 2 . Because DNA polymerase is unable
[ ]to completely replicate telomeric sequences 3,4 , it has
been proposed that progressive loss of telomere length
during cell division could act as a mechanism that limits the
[ ]replicative capacity of normal somatic cells 5,6 . Telom-
erase is a ribonucleoprotein enzyme that can use its RNA
[ ]7 component as a template and the telomerase catalytic
[ ]protein reverse transcriptase 8–10 for the addition of
telomeric repeats to the 3X ends of the chromosomes. Thus,
telomerase is thought to partially or completely compensate
for the progressive telomere erosion that would occur in its
absence. Because most normal somatic cells in vertebrates
do not express telomerase, it is thought that their telomeres
progressively shorten, undergo genomic instability, and
[ ]cease proliferating once a critical length is reached 11 . It
has been suggested that upregulation or re-expression of
telomerase may result in chromosomal stability leading to
[ ]continuous cell proliferation 6 .
Cancer is generally believed to be caused by accumula-
tion of multiple somatic mutations that subvert the normal
[ ]growth control mechanisms 12 . It has been suggested that
in most cancers cellular immortality is among the changes
[ ]required for sustained long-term growth 6,13,14 . Telom-
erase activity has been detected in 85% of tumors repre-
senting 15 cancer types, whereas most benign tumors and
somatic tissues have very low levels or lack detectable
[ ]telomerase activity 15,16 . Furthermore, in special
metastatic tumor types such as neuroblastoma stage IVs, in
which there is a high rate of spontaneous regression, telom-
erase activity is very low or not detectable, and telomere
[ ]lengths are considerably shorter than adjacent tissue 17 .
Thus, although telomerase is not necessarily required for
the initiation of a tumor, it is likely to be important in the
sustained growth of the tumor.
The diagnosis of melanoma can be made clinically in
[ ]80% to 90% of cases 18 , whereas the remainder require
histological examination for diagnosis. However, a certain
degree of ambiguity and thus indecision remains in the
[ ]histological diagnosis of melanoma 19 . To accurately pin-
point tumor cells and improve diagnosis, pathologists often
require the use of neoplastic markers. Telomerase has
been touted as such a marker. It has been shown previ-
( )ously that the human telomerase template RNA hTR can
be used in situ to distinguish between cancer cells and
[ ]normal cells in humans 20,21 and that levels of telomerase
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activity correlate well with the degree of hTR. Thus, in situ
techniques applied to tissue samples can now be used to
localize the presence of telomerase in melanoma cells
thereby, potentially aiding in diagnosis.
Traditionally, once the diagnosis is confirmed, tumors are
staged based on the clinical and/or radiographic evidence
of spread through the body. Clinical staging has been criti-
cal to determining treatment and prognosis. If there is no
(indication that melanoma has spread beyond the skin clini-
)cal stage I and II , treatment decisions are based on the
[ ]anatomical level of invasion 22,23 of tumor cells into the
skin. A number of histological parameters have been con-
sidered in an attempt to identify the greatest predictive
[ ]value for the development of metastases 24–26 and over-
all survival. Tumor thickness has consistently been shown
[ ]to have the most predictive value 27,28 . Two classification
schemes are used by pathologists, including the Breslow
( )thickness penetration depth measured in millimeters and
(the Clark classification five levels of penetration based on
) [ ]anatomic location of tumor cells in the skin 22,23,27,28 .
Because telomerase activity levels and RNA levels correlate
[ ]well with degree of malignancy 20,21 , it is possible that
determination of telomerase RNA expression or telomerase
activity levels in primary melanomas could help to deter-
mine more precisely the aggressive nature of individual
tumors, thus enabling more appropriate therapies and im-
proved prognosis.
In our present study, we analyzed and compared the
levels of telomerase activity with a variety of clinical and
histological parameters of a large group of cutaneous
melanocytic conditions, including compound or junctional
melanocytic nevi, malignant primary melanomas, subcuta-
neous metastasis of melanoma, and lymph nodes contain-
ing metastatic melanoma. We also used a telomerase RNA
in situ hybridization assay to determine the pattern of ex-
pression of hTR on formalin-fixed paraffin –embedded
melanocytic specimens.
Materials and Methods
Tissue Acquisition
All tissue samples were collected at the Istituto Der-
matopatico dell’Immacolata, Rome, Italy. Specimens of
melanocytic nevi, primary melanomas, and subcutaneous
metastases of melanoma were obtained under local anes-
(thesia from a total of fifty-eight patients with informed
)consent who underwent surgical removal of the lesion for
( )histological examination. Only relatively large )1 cm pri-
mary lesions were used for this study. Metastasized lymph
nodes were obtained from five patients who underwent
therapeutic regional lymph node dissection.
Specimens were received fresh in the surgical pathology
room. Those in which a reasonably obvious diagnosis of
benign or malignant nature was not possible were submitted
for standard histological evaluations. Obvious subcutaneous
metastases and grossly involved lymph nodes were bi-
sected, half of which were submitted for routine histological
evaluation and half stored for telomerase assays. Primary
lesions were serially sectioned, and at least three sections
displaying maximal thickness, as judged by gross inspec-
tion, were submitted for routine histological examination.
One section from the periphery of the pigmented lesion was
taken for in situ telomerase RNA analysis. Subcutaneous
and lateral portions of grossly uninvolved skin were then
removed with a scalpel so that only the clear-cut lesion and
the overlaying epidermis remained. Samples of normal skin
adjacent to primary lesions were also collected and tested
for telomerase activity.
Tissue samples were rapidly frozen and stored at y808C
until they were tested for telomerase activity. The entire
procedure from the time of surgery to the freezing step was
performed under sterile conditions and always completed
within 30 minutes.
Histopathologic Evaluation
Sections from each paraffin block were cut at 3-mm
thickness and stained with hematoxylin and eosin. The
diagnosis of melanoma or melanocytic nevus was estab-
lished according to the standard accepted criteria. Breslow
thickness was measured with a Leitz micrometer eyepiece
( ) (E. Leitz, Ruckleigh, NJ . Mitotic rate was rated as high 6
2) (mitotic figures per mm or low fewer than 6 mitotic figures
2)per mm . Melanoma patients were staged according to the
( )American Joint Commission on Cancer AJCC .
Preparation of Tissue Extracts
Tissue extracts were prepared as previously described
[ ]29 with the following modifications. Frozen specimens con-
taining dissected samples were thawed and subsequently
(transferred to Kontes homogenization tubes VWR Scientific
)Inc, Sugarland, TX containing 100 to 200 mL of ice-cold
( [( )lysis buffer 0.5% 3- 3-cholamidopropyl -dimethyl-am-
] ( )monio -1-propanesulfonate CHAPS , 10 mmol/L Tris–HCl
[ ]pH 7.5 , 1 mmol/L MgCl , 1 mmol/L ethyleneglycol-bis-2
( X X ( )
-aminoethyl ether-N,N,N ,N -tetraacetic acid EGTA , 5
[ ( )mmol/L mercaptoethanol, 0.1 mmol/L 4- 2-aminoethyl -
] )benzene-sulfonyl fluoride hydrochlorine , 10% glycerol . Ho-
(mogenization was carried out with disposable pestles VWR
) (Scientific, Dallas, TX attached to a cordless drill Black and
)Decker, Baltimore, MD and rotated at 450 rpm. Ho-
mogenates were left on ice for 30 minutes, followed by
centrifugation of lysates at 14,000 rpm at 48C for 20 min-
( )utes. Supernatants 80–160 mL were collected in fresh
(Eppendorf 1.5 micro tubes United Scientific Products, San
)Leandro, CA flash frozen in liquid nitrogen, and stored at
y808C. Before freezing, a 10-mL aliquot was transferred
into a separate Eppendorf 1.5 cc micro tube for protein
( )concentration analysis by using the BCA bicinchoninic acid
( )protein assay kit Pierce Chemical Co, Rockford, IL .
Telomeric Repeat Amplification Protocol
To evaluate the approximate levels of telomerase activity
in the different dissected compartments, telomeric repeat
( )amplification protocol TRAP assays were performed as
[ ]previously described 30,31 , including the use of an internal
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( ) [ ]telomerase assay standard ITAS 31 . Telomerase can
add TTAGGG repeats to a nontelomeric oligonucleotide TS
( X )5 -AATCCGTCGAGCAGAGTT that serves as the forward
primer. These elongation products can then be amplified by
( )polymerase chain reaction PCR with the reverse primer
( X [ ] )CX 5 - CCCTTA CCCTAA , resulting in a ladder of 6 base3
( )pair bp addition products.
Tissue extracts were normalized to 6.0 mg total protein
(per assay. The PCR-based TRAP Boehringer Mannheim,
)Indianapolis, IN assay was carried out in previously pre-
( )pared HotStart tubes 50 GIBCO BRL, Gaithersburg, MD
containing 100 ng of CX oligonucleotide beneath a wax
barrier and stored at 48C until needed. Aliquots containing
6.0 mg of total protein were assayed in 50 mL of reaction
( [ ]mixture 20 mmol/L Tris–HCl pH 8.3 , 68 mmol/L KCl, 1.5
mmol/L MgCl , 1 mmol/L EGTA, 0.05% Tween 20, 0.1 mg2
( )of TS primer Midland Certified Reagent Co , 0.5 mmol/L T4
gene 32 protein, 50 mmol/L of each deoxynucleotide
triphosphate, 2 U of Taq DNA polymerase, 4 mCi of
[y32 ] [ ] y18 ( )P dCTP 10 mCi/mmol , and 5=10 g 5 attograms
[ ]of ITAS 31 . The reaction mixture was incubated at room
temperature for 30 minutes to allow telomerase to extend
(TS primer followed by a 31-cycle PCR amplification ther-
mocycling block with heated lid, HB-60, MJ Research, Wa-
)tertown, MA of the telomeric products. Analysis of 20 mL of
the PCR mixtures was performed on 10% nondenaturing
acrylamide gels. Gels were fixed in 0.5 mol /L NaCl, 50%
( )ethanol, and 40 mmol/L sodium acetate pH 4.2 on a
rocking table for 30 minutes at room temperature. Excess
fixing solution was removed, and gels were exposed at
room temperature to phosphor screens overnight and visu-
alized on a PhosphorImager with ImageQuant software
( )Molecular Dynamics, Sunnyvale, CA .
Quantitation of Telomerase Activity
The telomerase assay can be made semiquantitative by
y18 ( )the inclusion of 5=10 g 5 attograms of an ITAS, a
150-bp fragment containing TS and CX sequences at the
ends. That is co-amplified along with the telomerase ladder
[ ]30,31 . The levels of telomerase activity were normalized to
that of the ITAS. The inclusion of ITAS not only permits
relative quantitation between samples, it also aids in the
identification of false-negative samples that contain Taq
polymerase or other PCR inhibitors. The relative telomerase
activity was determined by calculating the ratio of the inten-
sity of the area under peaks representing telomeric repeats
( )TRAP ladder to the area under the peak representing
amplified ITAS. When the levels of telomerase activity were
too high to allow amplification of ITAS, ten-fold dilutions of
these samples were assayed for telomerase activity. Tripli-
cate aliquots from selected samples were analyzed, and
consistent results were obtained. Pooled ratio results from
each sample group were then compared for statistical signif-
icance by using nonparametric analyses and rank method
( )JMP software, Cary, NC . The Wilcoxon/Kruskal Wallis
tests combined with the Tukey-Kramer multiple mean com-
parisons procedure and the ANOVA/t test procedures, were
used for all independent groups. All image operations and
calculations were performed by using ImageQuant software
( ) (Molecular Dynamics and Microsoft Excel 5.0 Microsoft
)Corporation, Redmond, WA .
Preparation and Prehybridization of Tissue Sections for In
Situ Hybridization
( )Formalin-fixed paraffin–embedded 3-mm tissue sec-
(tions were placed onto Superfrost/Plus slides Fisher Scien-
)tific, Pittsburgh, PA . The sections were then deparaffinized,
( )rehydrated in phosphate buffered saline PBS , and treated
( ) (with proteinase K 20 mg/mL in 50 mmol/L Tris-HCl pH
)7.5 , 5 mmol/L EDTA, for 20 minutes at room temperature.
After rinsing for 5 minutes in PBS, sections were postfixed
in 4% paraformaldehyde/PBS, rinsed in water, and acety-
lated in freshly prepared 0.25% acetic anhydride/0.1 mol/L
triethanolamine for 10 minutes. The slides were then dehy-
drated in gradually increasing concentrations of ethanol
before hybridization.
Probe Preparation for In Situ Hybridization
( )The plasmid pGEM-5Z Promega Corp, Madison, WI ,
(containing a full-length hTR complementary DNA 560 nu-
)cleotides , obtained from the Geron Corp, Menlo Park, CA,
( )was used as a template to generate sense control and
[35 ]antisense probe. S UTP-labeled single-stranded RNA
(probes were synthesized according to manufacturer’s Amb-
)ion, Inc, Austin, TX conditions. Transcripts were alkali hy-
drolyzed to generate probes, with an average length of 200
nucleotides for efficient hybridization, purified with G-50
( )column Boehringer Mannheim Corp, Indianapolis, IN , and
precipitated in ethanol. The probes were then resuspended
in 30 mL of 100 mmol/L dithiothreitol. The specific activity of
the radiolabeled probes, aliquoted and stored at y808C
until use, was approximately 3 to 5=106 cpm/mg template
DNA.
Hybridization and Washing Procedures
Sections were hybridized overnight at 528C in 50% deion-
(ized formamide, 0.3 mol/L NaCl, 20 mmol/L Tris–HCl pH
) ( )7.5 , 5 mmol/L EDTA, 10 mmol/L NaH PO pH 8.0 , 10%2 4
dextran sulfate, 1= Denhardt’s, 500 mg/mL total yeast
RNA, 10 mmol / L dithiothreitol, and 50,000 cpm / mL
35S-labeled cRNA probe. The slides were then subjected to
stringent washing at 508C in 5= SSC, 10 mmol/L dithio-
threitol for 30 minutes, at 658C in 50% formamide, 2= SSC,
10 mmol/L DTT for 30 minutes and washed twice at 378C in
( )0.4 mol/L NaCl, 10 mmol/L Tris-HCl pH 7.5 , 5 mmol/L
EDTA for 10 minutes before treatment with 20 mg/mL
RNase A at 378C for 30 minutes. Following washes in 2=
SSC and 0.1= SSC for 1 hour at 378C, the slides were
(dehydrated and dipped in Kodak Eastman Kodak Co.,
)Rochester, NY NTB-2 nuclear track emulsion and exposed
for 3 to 4 weeks in light tight boxes with desiccant at 48C.
(The slides were developed in Kodak Dektol developer 3.5
) ( ) ( )min , washed in water 30 sec , fixed in Kodak fixer 6 min ,
rinsed in water, counterstained in hematoxylin, dehydrated,
( )coverslips mounted with Paramount Sigma, St. Louis, MO ,
(and finally observed under light microscope Olympus
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)America Inc., Lake Success, NY in both bright and dark
fields, followed by photography. In the present study sam-
ples were considered hTR positive if uniformly dense silver
grains were overlying tumor nuclei similar to those observed
in the normal adult testis. Specimens were considered neg-
ative if there was complete absence of background hy-
bridization similar to sense control.
Results
Telomerase Activity Is Detected at Highest Levels in Metas-
tases of Melanoma
Sixty-six samples from a total of sixty-three patients with
several different types of melanocytic lesions and adjacent
(skin were examined for telomerase activity Figure 1 and
)Table 1 . Telomerase activity was detected at much higher
levels in subcutaneous metastases of melanoma and
metastasized lymph nodes when compared with other
( )melanocytic lesions Table 1 . The mean relative telom-
erase activity in subcutaneous metastases of melanoma
and metastasized lymph nodes was 54.5 and 56.5, respec-
tively, compared with primary melanomas and benign nevi
in which relative telomerase activities did not exceed 1.9.
This difference between metastatic and nonmetastatic
(melanomas was statistically highly significant P value-
)0.0001 as determined by the Wilcoxon/Kruskal Wallis test
combined with the Tukey-Kramer multiple mean compari-
son. Although, much lower levels of telomerase activity
( )were detected in primary melanomas Table 1 , even these
were significantly elevated when compared with telomerase
activity from adjacent control skin samples from the same
( )patient P values0.02, ANOVA/t test . Very low telom-
erase activity levels were detected in benign melanocytic
( )lesions e.g., compound and junctional melanocytic nevi ,
but these were not statistically significant when compared to
( )adjacent control tissues P values0.1809, ANOVA/t test
( )Figure 1 and Table 1 .
Telomerase Activity Correlates with the Level of Invasion,
Tumor Thickness, and the Mitotic Rate in Malignant
Melanoma
Telomerase activity of primary melanomas in cases of
clinical stage I and II disease were quantified and compared
(with the different anatomical levels of invasion Clark II to
)IV . The mean relative telomerase activity levels in primary
(Figure 1. Representative gel of melanocytic specimens for telomerase activity: benign lesions blue nevi, compound
) ( )melanocytic nevi, junctional melanocytic nevi ; malignant lesions primary melanoma Clark II, Clark III, and Clark IV ;
benign lymph node, metastatic lymph node, and a distal subcutaneous metastatic melanoma. Negative control: lysis buffer;
( )positive telomerase controls a human breast epithelial cell line immortalized with human papilloma virus 16E6/E7 : 10
cells, 100 cells, and 1000 telomerase-positive cells. ITAS, a 150-bp fragment containing TS and CX sequences at the
ends, co-amplifies with the telomerase ladder. It is included for semiquantitative telomerase activity level analyses and to
detect PCR or Taq polymerase inhibitors.
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Table 1. Clinical Stage and Level of Invasion Compared With Telom-
erase Activity.
Number of Mean Relative Standard
Specimens Telomerase Error
Activity
)Clinical Stage
†I–II 18 1.6 0.57
‡III 5 56.5 14.2
§IV 8 54.5 12.3
Benign nevi
CMN/JMN 35 0.7 0.30
Primary melanoma
5Clark I NA NA —
¶Clark II 1 0.02 —
aClark III 4 1.1 1.0
))Clark IV 13 1.9 0.7
Metastases of melanoma
LNM 5 56.5 14.2
SCM 8 54.5 12.3
)Staging according to The American Joint Commission on Cancer
( )AJCC .
†Primary melanoma without clinically palpable nodes.
‡Primary melanoma with clinically palpable nodes.
§Patients present with distant metastases.
5 In situ.
¶Penetrates papillary dermis.
aFills papillary dermis.
))Penetrates reticular dermis.
CMN/JMN, compound melanocytic nevi/junctional melanocytic nevi; NA,
not available; LNM, lymph node metastases; SCM, subcutaneous
metastases of melanoma.
melanoma were as follows: Clark IIs0.02, Clark IIIs1.1,
and Clark IVs1.9. Thus, in melanomas that have filled the
( )papillary dermis Clark III and penetrated the reticular der-
( )mis Clark IV , telomerase activity levels were higher than in
( )those melanomas with less invasive behavior Table 1 .
Telomerase activity was also compared to the Breslow
(thickness among eighteen primary melanomas Clark II–IV,
)clinical stages I and II . Relative mean telomerase activity
detected in tumors with thicknesses less than 0.76 mm was
0.2; between 0.76 and 1.69 mm, 2.4; between 1.70 and
( )3.60 mm, 1.7; and greater than 3.60 mm, 2.5 Table 2 .
High mitotic rate lesions had a relative mean telomerase
activity of 3.6, whereas low mitotic rate lesions had relative
( )mean telomerase activity of 0.9 Table 2 . These results
( )were statistically significant P values0.03, ANOVA/t test .
However, when telomerase levels in radial versus vertical
growth patterns were compared, no significant difference is
( )noted Table 2 .
Telomerase Activity Compared With the Degree of Lympho-
cytic Infiltrate
It has been shown previously that leukocytes express low
[ ]levels of telomerase activity constitutively 32,33 and can
[ ]increase with antigen stimulation 33 . Furthermore, when
the number of leukocytes in skin are increased acutely by
inducing dermatitis with cutaneous application of poison ivy
antigen, telomerase levels increase compared with normal
[ ]control skin 29 . This suggests leukocytic infiltration could
contribute to the telomerase activity detected in inflamma-
tory conditions of skin, including those associated with ma-
Table 2. Clinical Features of Primary Melanoma Compared With Telom-
erase Activity.
Number of Mean Relative Standard
Specimens Telomerase Error
Activity
( )Breslow thickness mm
- 0.76 6 1.2 1.00
0.76–1.69 5 2.4 1.50
1.70–3.60 6 1.7 0.65
)3.60 1 2.5 —
)Mitotic rate
High 7 3.6 0.96
Low 11 0.9 0.59
†Growth pattern
Radial 2 2.0 1.75
Vertical 16 1.6 0.02
‡Lymphocyte infiltration
0 2 0.3 0.2
10 5 2.0 1.2
20 2 2.7 1.3
50 3 0.3 0.1
60 1 4.5 —
70 3 2.6 2.5
80 1 0.03 —
)HighsG 6 mitotic figures per mm2; lows- 6 mitotic figures per mm2.
† ( ) (Radialshorizontal growth -1.0 mm ; verticals vertical growth G1.0
)mm .
‡Expressed in terms of percentage of lymphocytes in the total cell
( )population 100% constituted by melanocytes and lymphocytes.
lignant melanoma. Lymphocytic infiltrates were carefully
quantitated on all samples and then correlated with the level
of telomerase activity. No consistent trends were noted
( )Table 2 .
In Situ Telomerase RNA Detection
Because the tissue samples tested for telomerase activ-
ity contained varying quantities of nonmelanocytic cells, the
possibility exists that their presence could influence the
(relative amounts of telomerase activity detected e.g., dilu-
)tion effect or inhibitory effect . Attempting to use a more
sensitive measure of telomerase expression, we undertook
( )an in situ assay for the detection of hTR Table 3 . This had
several advantages, including allowing us to use archived
Table 3. In Situ Hybridization hTR in Several Melanocytic Conditions.
)Number of In Situ hTR
Specimens
Benign nevi
CMN/JMN 9 —
Primary melanoma
†Clark II NA NA
‡Clark III 1 q
§Clark IV 10 q
Metastases of melanoma
LNM 2 q
SCM 4 q
)G10 grains over the nucleussq; -10 grains over the nucleussy.
†Penetrates papillary dermis.
‡Fills papillary dermis.
§Penetrates reticular dermis.
CMN/JMN, compound melanocytic nevi/junctional melanocytic nevi; NA,
not available; LNM, lymph node metastases; SCM, subcutaneous
metastases of melanoma.
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formalin fixed paraffin-embedded specimens, and to identify
the exact cell type with increased hTR. Previous studies
have shown that in situ hTR could easily distinguish cancer
cells from normal cells and that the levels of hTR signal
[ ]correlated well with telomerase activity 20,21 . In situ hTR
hybridization evaluation of a Clark’s level IV primary
melanoma confirmed that the telomerase activity detected
in TRAP assays originated from tumor cells because no
hTR signals above background levels were observed in
(lymphocytes or other cell types in the specimens Figure
)2A–I . In areas of tumor cell invasion, large tumor cells with
an abundance of cytoplasm were observed to contain
( )hTR-positive nuclei Figure 2G–H . A pagetoid distribution
(of large melanoma cells throughout the epidermis Figure
) ( )2A were clearly hTR positive Figure 2B–C . Under dark
field microscopy, the hTR-positive signals were even more
apparent in dermal nodules and intraepidermal collections
( )of malignant cells Figure 2C, F, and I . All malignant
melanomas were positive for hTR, whereas benign lesions
( )compound/ junctional melanocytic nevi, data not shown
were either negative or had near-background levels of hTR
in areas where no telomerase activity is typically detected
( ) [ ]e.g., dermis or suprabasal layers of epidermis 29,34 .
Discussion
We previously reported telomerase activity is upregulated in
skin cancer and that the highest levels were in samples
[ ]containing basal cell carcinomas 29 . Lower telomerase
levels were observed in clinically more malignant tumors
such as squamous cell carcinoma and primary cutaneous
[ ]melanomas 29 . These findings suggested that aggressive
behavior did not directly correlate with increased levels of
telomerase activity. However, because the number of
[ ]melanoma samples analyzed in the previous study 29 was
small and the lesions were thin, they were thought to be
early in their malignant progression. Therefore, the present
study was undertaken to evaluate the expression levels of
telomerase activity in benign and malignant cutaneous
melanocytic lesions with various degrees of invasion. We
observed that the highest levels of telomerase activity were
detected in metastases of melanoma, whereas the lowest
levels of telomerase activity were in benign nevi and low
( )grade melanomas e.g., Clark II with little degree of inva-
( )sion see Table 1 . Regarding Breslow thickness and telom-
erase activity levels, two groups can be distinguished: those
less than 0.76 mm and those greater than 0.76 mm.
Melanomas with a Breslow thickness less than 0.76 mm
( )93% patient survival at eight years showed telomerase
levels 8- to 10-fold lower than those detected in thicker
( )melanomas )0.76 mm known to behave more aggres-
( )sively see Table 2 . Similarly, telomerase activity levels
detected in high mitotic rate lesions were four times higher
( )than those with low mitotic rate lesion see Table 2 . Degree
of infiltrating lymphocytes did not correlate with telomerase
activity levels, and lymphocytes had very low or failed to
express hTR, suggesting that these cells contributed little, if
( )any, to the activity measured see Table 2 . Likewise, no
significant difference in telomerase levels was noted be-
( )tween radial and vertical growth see Table 2 . These re-
sults suggest that the level of telomerase activity increases
with increasing thickness of the lesions, which reflects a
greater tumor cell volume and a lesion that has acquired
more aggressive properties. Results in this article do not
( )address the mechanism s involved in the dramatic upregu-
lation of telomerase activity in metastatic melanoma lesions.
Telomerase activity levels in metastatic melanoma are simi-
lar to those detected in metastatic lesions of other tumor
[ ]types 15,29 , and possible mechanisms for the increased
telomerase activity are transcription upregulation of human
telomerase reverse transcriptase—the catalytic subunit of
( )telomerase— hTERT or hTERT gene amplification.
Even though hTERT in situ hybridization would be an-
other potential way of detecting the presence of telomerase
in cell and tissue samples, alternative splicing variants of
hTERT occurs in some telomerase-negative cells, resulting
( )in false-positive signals data not shown . Thus, to visualize
the pattern of telomerase expression among melanomas
with different levels of invasion, we used telomerase RNA in
situ hybridization techniques. Individual invading melanoma
cells were found to be telomerase positive regardless of
( )their location in the skin or lymph node Table 3 . Thus,
telomerase RNA may be a useful molecular marker for
(determining the extent of invasion e.g., among primary
)melanomas and to identify the presence of metastases
within lymph nodes and in distant cutaneous tissue. This
could potentially improve the accuracy of staging and influ-
ence the choice of treatment. However, additional investiga-
tions are needed to address the possible correlation of hTR
expression level per tumor cell with malignant potential.
Maintaining telomere length stability via expression of
telomerase activity in cells may be important in carcino-
genesis. Our results suggest that normal nevus cells and
melanocytes fail to express telomerase or do so at very low
levels. Documenting the correlation of increasing levels of
functional telomerase with increasing malignant potential in
melanomas strongly suggests that it is not only a feature of
malignancy, but quantitation of its activity that may also
have clinical prognostic value. Although additional studies
must be done to fully characterize the role played by telom-
erase in melanoma carcinogenesis, it is hoped that the use
of new and more efficient telomerase detection assays
could potentially assist in the diagnosis of borderline le-
sions.
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